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Summary The pathologic mechanisms of chronic obstructive pulmonary disease
(COPD) most certainly involves neutrophil granulocytes, cytotoxic T-cells, maco-
phages and mast cells. The aim of this study was to investigate the relation between
the number of mast cells in different compartments in bronchial biopsies of central
proximal airways to structural changes, lung function tests and emphysema detected
by high resolution computed tomography (HRCT).
Twenty nine asymptomatic smoking and 16 never-smoking men from a population
study were recruited. Central bronchial biopsies were stained to identify mast cells
by immunohistochemistry. The number of mast cells in the epithelium, lamina
propria and smooth muscle as well as epithelial integrity and thickness of the
tenascin and laminin layer were determined.
Smokers had increased numbers of mast cells in all compartments (Po0.001).
Structural changes were correlated to mast cell numbers with the closest
associations to mast cell numbers in the smooth muscle [epithelial integrity
(Rs¼0.48, P¼ 0.008), laminin layer (Rs¼ 0.63, P¼ 0.0002), tenascin layer
(Rs¼ 0.40, P¼ 0.03)]. Similar correlations between mast cells and lung function
tests were seen [functional residual capacity (FRC) (Rs¼ 0.60, P¼ 0.0006), total lung
capacity (TLC) (Rs¼ 0.44, P¼ 0.02) and residual volume (RV) (Rs¼ 0.41, P¼ 0.03)].
No correlations could be detected between mast cells and FEV1 or to emphysema.
Smoking is associated with an increase of mast cells in all compartments of the
bronchial mucosa, including smooth muscle, and this is related to altered airway
structure and function.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Chronic obstructive pulmonary disease (COPD)
is globally a common cause of morbidity and
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mortality. Progressive airway obstruction and
chronic airway inflammation are hallmarks of the
disease. However, it is not clear how the mechan-
isms induced by smoking are involved in the
development of COPD.
The inflammatory features of COPD are charac-
terised by neutrophil leucocytes1,2 in the bronchial
lumen. There is a relation between activation of
neutrophils and decreased lung function.3–5
Although some groups have demonstrated the
presence of an increased number of neutrophils in
the bronchial mucosa in smokers with severe
COPD,6–8 it appears that the inflammatory features
in the bronchial mucosa differ from those in the
bronchial lumen. Several independent groups have
shown a relation between increased numbers of
CD3þ cells (T lymphocytes), CD8þ T cells (cyto-
toxic T lymphocytes) and a reduced FEV1.
9–12 In
smokers with chronic bronchitis, increased numbers
of macrophages have been found in the bronchial
mucosa and in the bronchial glands.6,7 Also eosino-
phils were increased, although not degranulated as
in asthma,13 in the bronchial mucosa and in BAL in
smokers with chronic bronchitis compared to those
without this.6,14 The number of mast cells in the
bronchial mucosa were increased in smokers with
COPD compared to smokers without this.15–18 Mast
cells in the airway wall may thus be important in
the development of smoking related changes prior
to the development of COPD. Recently, infiltration
of bronchial smooth muscle by mast cells has been
associated with the variable airflow obstruction and
hyperresponsiveness characteristic of asthma.19
Such a mast cell myositis was not a feature of
eosinophilic bronchitis.
We showed recently that neutrophils, eosino-
phils, macrophages and mast cells are increased in
asymptomatic smokers compared to never-smo-
kers.20 The smokers also had structural changes
such as increased tenascin, laminin layers and
significantly decreased epithelial integrity. The
increased thickness of laminin and tenascin layers
were correlated to the number of eosinophils and
mast cells, indicating a role for these cells in the
remodelling process.
The aim of this study was to further investigate
the distribution of mast cells in different compart-
ments in the bronchi of asymptomatic smokers in
relation to structural changes and clinical signs. We
hypothesised that, in asymptomatic smokers there
are increased numbers of activated mast cells in
central bronchial biopsies and that these mast cells
might be localised to the smooth muscle, as earlier
described in asthmatics. Further, we hypothesised
that, in smokers these mast cells, mainly localised
to the smooth muscle, are related to structural
changes, lung function tests and emphysematous
changes on high resolution computed tomography
(HRCT). Our results were compared with results
from a randomly selected never-smoking group
recruited from the same population study.
Material and methods
Study population
The subjects were recruited from the population
study ‘‘Men born 1933 in G .oteborg’’.21 In a previous
paper the sampling procedure has been described
in detail.5 All subjects that had sought medical
attention for any airway disease (including asth-
ma), congestive heart failure, angina pectoris or
any other severe disease were excluded. Bronchial
biopsies were collected from 30 smokers and 18
never-smokers. Fourteen of the smokers were light
smokers (o15 cigarettes/day) while the rest
ðn ¼ 15Þ were heavy smokers (X15 cigarettes/
day). The mean number of pack-years was 32714
(median 32, range 9–56). Lung function differed
between smokers and never-smokers as well as
emphysema score (Table 1).22
The study was approved by the local Ethics
Committ !ee at G .oteborg University, G .oteborg
Sweden, and informed consent was obtained.
Fibreoptic bronchoscopy and sample
collections
Premedication was given with diazepam 5mg orally
followed by 0.5ml morphine-scopolamine intra-
muscularly. If the person had a history of kidney or
gall bladder disease, pethidine 75mg intramuscu-
larly and atropine 0.5mg subcutaneously were
given instead of morphine-scopolamine. Additional
diazepam (2.5–5mg) intravenously was given dur-
ing the bronchoscopic procedure in some cases.
All persons were given terbutaline 0.25mg/dose
2 inhalations t.i.d. in a nebulizer to avoid un-
expected bronchoconstriction during the proce-
dure. Local anaesthesia was given initially with 1%
tetracaine-spray in the mouth and laryngeal tract.
Additional anaesthesia was applied through the
bronchoscope channel for the lower respiratory
tract. The bronchoscopy was performed transorally
with an Olympus flexible fibreoptic bronchoscope
(Tokyo, Japan). The subjects were examined in a
supine position by one experienced bronchoscopist.
Oxygen saturation was measured with an Ohmeda
Pulse Oximeter (Louisville, USA) during the
bronchoscopy and supplemental oxygen was given
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at a rate of 2–3 l/min through a nasal catheter
when needed.
All bronchoscopies were made between 8 AM and
10 AM. Bronchial biopsies (3–4 biopsies/subject)
were taken with an alligator forceps from the main
carina between the right and left main bronchus.
The biopsies were gently removed from the forceps
immediately placed in a sterile moistened chamber
and transported to the laboratory for further
processing. Twenty nine of 30 biopsies from the
smokers and 16 out of 18 biopsies from the never-
smokers were evaluable based on size and
morphology.
Immunohistochemistry
The mast cells were identified with monoclonal
antibodies on frozen sections. The anti-tryptase
antibody 1, AA1 (M 7052, Dako, Glostrup, Den-
mark), for the identification of mast cells, was used
at a final concentration of 0.00315mg/ml, Mono-
clonal antibodies to Laminin (M 0638) and Tenascin
(M 0636; Dako) were used on frozen sections at
concentration of (0.0065mg/ml and 0.047mg/ml,
respectively). The distinction between lamina
propria and smooth muscle was confirmed by
immunostaining of smooth muscles with anti-actin
antibodies. Monoclonal antibodies to anti-human
smooth muscle actin (M 0851; Dako) were used on
frozen sections at a concentration of 3.00mg/ml.
The bronchial biopsy specimens taken from the
main carina were frozen immediately in melting
propane previously cooled in liquid nitrogen.
Frozen biopsies were kept in liquid nitrogen until
sectioned. The samples were attached to the
specimen holder of a cryostat microtome (Microm,
HM 500M, Heidelberg, Germany) in a drop of OCT
compound (Tissue-Tek, Miles, Elkhart, IN, USA) and
cut in sections with a thickness of 4 mm. After
drying in air at room temperature, the sections
were wrapped in aluminium foil and stored at
701C until they were used for immunohistochem-
istry.
The sections were thawed and then fixed with
undiluted Ortho Permeafix (Ortho Diagnostics,
Raritan, USA) for 40min at room temperature prior
to incubation with antibodies to mast cell markers
while laminin and tenascin markers fixed with
aceton for 10min at room temperature. In pre-
liminary experiments it was found that fixation and
permeabilization with the commercial reagent,
Ortho Permeafix, produced comparable results in
immunocytochemistry to the paraformaldehyde
saponin method, but resulted in improved structur-
al preservation. Sections were incubated with
monoclonal antibodies at room temperature in a
humid chamber for 1 h and the biopsies were
processed as previously described.23
Microscopic evaluation of sections
All the specimens were coded and examined by the
microscopist without any knowledge of the current
smoking habits. Microscopic evaluation of two
separate sections from each of two different
biopsies was carried out with a Nikon ECLIPSE
E800 microscope. The number of cells in the
mucous membrane was counted in the whole
specimen and the data were converted to an area
of 1mm2 of tissue. Cell numbers were counted
separately in three different compartments, i.e. in
the epithelium, in the lamina propria and in the
smooth muscle. The areas of the different com-
partments were outlined and the contained area
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Table 1 Lung function and emphysematous changes in the subjects.
Smokers Never-smokers P
ðn ¼ 29Þ ðn ¼ 16Þ
TLC 97714 (71–125) 99710 (80–115) n.s.
RV 116732 (50–173) 98727 (64–170) n.s.
FRC 106720 (74–162) 104725 (68–171) n.s.
VC 87712 (63–113) 96711 (76–118) 0.021
FEV1 92714 (67–134) 109714 (91–146) 0.0005
DLCO 85716 (51–135) 96715 (70–131) 0.015
Emphysematous changes 12 0 o0.0001
Emphysema score 0.7470.42 (0.17–1.63) F
(All values are % predicted, except for emphysematous changes where number of subjects with emphysema are expressed, P is
according to Mann–Whitney’s nonparametric test, except for emphysematous changes where P is according to Fishers’ exact
test).
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was measured using image analysis with a Bit Pad
two data tablet (Summagraphics Corp., Seymour,
CT, USA) with a Synoptics (Cambridge, UK) Synapse
framestore and software package after calibration
with the aid of a stage squared micrometer. The
variation in cell counts and estimation of structural
changes between the two microscopic sections
varied between 3% and 5% (% coefficient of
variation). Degranulating and non-degranulating
mast cells were identified in the specimen. Mast
cells were categorised as degranulating mast cells
when extracellular deposition of anti-tryptase
stained material was observed. Figure 1 shows the
number of mast cells in different compartments in
both smokers and never-smokers. Figure 2 shows
degranulating and non-degranulating mast cells
in different compartments in smokers and never-
smokers.
The epithelial integrity of the bronchial wall of
the subjects from the different groups was assessed
by light microscopy in 4 mm thick frozen sections
stained with Mayer’s hematoxyline. Epithelial
integrity was estimated using a 10 objective and
sidearm light microscopic attachment that allowed
the image of the section to be projected onto a
computer screen. The total length of the basement
membrane and the length of intact epithelium in
the section through each biopsy were deter-
mined.18 The total length of intact epithelium
was expressed as a percentage of the total length
of basement membrane present in each biopsy.
The measurement of the thickness of the
tenascin and laminin layers (in mm) was performed
in 4-mm thick immunolabelled frozen sections using
a 10 objective and a computerised image analysis
system after calibration with the aid of a stage
micrometer as described above. The measurements
were carried out on 100 randomly selected sites
per section and the results expressed as the means
of these measurements.
Lung function tests
In all subjects’ lung volumes, spirometry and
diffusion capacity were determined. Lung volumes
were obtained by a flow displacement body
pletysmograph (Body box 2800 SensorMedics Co,
Bilthoven, The Netherlands). Forced expired vo-
lume in one second (FEV1) and vital capacity (VC)
were obtained on a water sealed regularly cali-
brated bell spirometer. Carbon monoxide transfer
(DLCO) was assessed by the single breath method
with standard equipment (SensorMedics 2200,
SensorMedics Co, Bilthoven, The Netherlands). We
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Figure 1 Number of mast cells per mm2 in different
compartments in asymptomatic smokers (AS) and never-
smokers (NS) (P according to the Mann–Whitney’s test).
Figure 2 Cryostat sections of bronchial biopsy speci-
mens for AA1 positive cells in (a) asymptomatic smokers
and (b) never smokers. Mast cell degranulations were
present in the smooth muscle (SM) and lamina propria
(LP) of asymptomatic smokers. Few mast cells were
found in the tissues of never smokers. Stain: Mayer’s
hematoxyline. Original magnification:  340.
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used the European Respiratory Society reference
values24 for lung volumes and spirometry and the
reference values according to Salorinne25 for DLCO.
High resolution tomography
The subjects were examined by HRCT on the same
day as the investigation of lung function. The entire
thorax was scanned in full inspiration with the
subject supine. A Picker PQ2000 (Picker Interna-
tional, Cleveland, USA) was used. Slice thickness
was 1.5mm and there was 30mm between slices.
Scan time was 1 s and exposure data were 130 kV
and 200mA. The images were reconstructed with
the sharp algorithm of Picker and displayed on
1400  l700 film with 6 images/film. Window width
was set to 1400HU and window level to 400HU.
Two experienced thoracic radiologists evaluated
the images independently without knowledge of
smoking history. Areas of low attenuation and/or
sparse and stretched vessels without intervening
thick walls were classified as emphysematous
lesions. The extent of emphysematous lesion in
each lung in each slice was classified on a
scale from 0 to 4 (0¼ no emphysematous lesions,
1¼ 1–25% of lung area, 2¼ 26–50%, 3¼ 51–75% and
4X75%).26 The scores for each lung in each slice
were added and divided by the number of slices
leaving a mean score for each subject. No effort
was made to classify the severity of the lesions. The
mean value of the radiologists’ scores was used for
comparison with other investigations. The details
of the evaluation have been presented previously.22
Questionnaire
The questionnaire was a modified version of the
European Community Respiratory Health Survey.27 It
was divided into three principal parts. The first
section, symptoms, contained items concerned with
the level of symptomatology, including wheezing,
dyspnea, cough, sputum production, one non-
specific question, ‘‘Do you ever have trouble with
your breathing?’’; if the answer to this last question
was yes, the subject was asked to indicate whether
this was continuously/repeatedly/only rarely. The
subject was also asked if they had asthma or if any
doctor had told them to have asthma. The second
section contained detailed questions about smoking
habits. In the third section, the subjects were asked
about other diseases and concomitant medication.
The subjects answered the questionnaire before any
lung function test, bronchoscopy or HRCTwas done.
All subjects answered the questionnaire except for
one smoker and one never-smoker.
Statistics
All the statistics were calculated using non-para-
metric tests. Comparisons between asymptomatic
smokers and never-smokers were performed with
the Mann–Whitney U-test. For correlations within a
group, Spearman’s rank correlation test was used.
A P-value of o0.05 was regarded as statistically
significant. Calculations were performed on a PC
using the statistical package Statistica for Windows
v. 5.5 s from Statsoft (USA).
Results
Mast cells in central bronchial biopsies in
different mucosal compartments
The number of mast cells were counted in different
mucosal compartments in the biopsies. As shown in
Fig. 1 we found significantly ðPo0:001Þ elevated
numbers of mast cells in biopsies from asympto-
matic smokers in all three compartments (epithe-
lium, lamina propria and smooth muscle). There
was no statistically significant difference between
the number of mast cells in lamina propria or
smooth muscle. However, both these compart-
ments demonstrated significantly higher numbers
of mast cells than in the epithelium ðPo0:001Þ: The
differences between the mucosal compartments
were seen for both asymptomatic smokers and
never-smokers. Figure 2 shows the immunostaining
of mast cells in biopsies from asymptomatic
smokers and never-smokers. This figure demon-
strates that mast cells in asymptomatic smokers are
degranulated to a larger extent than in biopsies of
never-smokers. We also found that mast cells in the
epithelium of asymptomatic smokers showed less
signs of degranulation than the two other mucosal
compartments (results not shown).
The numbers of mast cells and degranulated mast
cells were similar if smokers were compared with
respect to present smoking habits (heavy/light
smokers) or due to smoking history (more/less than
35 pack-years). The number of mast cells did not
correlate to the number of pack-years.
Relationships between numbers of mast cells
in different mucosal compartments and
structural changes in the mucosa
As reported before,20 we found highly significant
correlations between the total number of mast
cells in central bronchial biopsies and other
structural changes in the biopsies of asymptomatic
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smokers. In this study, we found significant correla-
tions between mast cells in all three compartments
and structural changes (Table 2). This was seen in
asymptomatic smokers but not in never-smokers.
The strongest correlation was seen between mast
cells in the smooth muscle compartment and the
thickness of the laminin layer (Rs¼ 0.63, Po0.001).
Similar correlations were obtained when the
number of degranulated mast cells were counted.
Mast cells in central bronchial biopsies in
relation to lung function tests
In smokers, we found significant positive correla-
tions between the total number of mast cells and
FRC, RV and TLC (Fig. 3). In never-smokers, we did
not find any significant correlation. In smokers, we
investigated the relation between the numbers of
mast cells in the three different mucosal compart-
ments to lung function tests (Table 3). The
strongest positive correlations were seen between
mast cells in the smooth muscle compartment and
FRC, TLC and RV, respectively. The correlations
were of similar magnitude when the number of
degranulated mast cells in relation to lung function
tests was considered (results not shown). In
smokers, we did not find any significant correlation
between the number of mast cells and FEV1.
Mast cells in central bronchial biopsies in
relation to emphysema on HRCT
In smokers, we found no significant difference in
the total number of mast cells among subjects with
and without emphysema (22.876.3 vs. 22.5710.6,
P¼ n.s.). The results were similar when the number
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Table 2 Correlations between the number of mast cells in different compartments and structural changes in
smokers (n¼ 29).
Epithelium Lamina propria Smooth muscle
Rs P-value Rs P-value Rs P-value
Tenascin layer (mm) 0.40 0.030 0.36 0.052 0.40 0.031
Laminin layer (mm) 0.35 0.059 0.39 0.037 0.63 0.0002
Epithelial integrity (mm) 0.43 0.018 0.46 0.011 0.48 0.0079
(Rs¼ Spearman rank correlation coefficient, P according to the Spearman rank correlation test).
(b)
50
100
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0 25 50
Total number of mast cells /mm2
Rs = 0.44 
p  = 0.02
(c) 
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p = 0.006
Figure 3 Correlations between (a) functional residual capacity (FRC) (% predicted); (b) total lung capacity (TLC) (%
predicted); (c) residual volume (RV) (% predicted), and the total number of mast cells per mm2 in smokers ðn ¼ 29Þ
(Rs¼ Spearman rank correlation coefficient, P according to the Spearman rank correlation test).
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of mast cells in the three different mucosal
compartments were considered (results not
shown). The total number of mast cells did not
relate to emphysema score.
Mast cells in central bronchial biopsies in
relation to respiratory symptoms
Even if these subjects did not spontaneously report
respiratory symptoms, some reported respiratory
symptoms when approached with a question-
naire.28 In smokers, we found no significant
differences in the total number or in the number
of mast cells in the three different mucosal
compartments, in those with vs. those without
different respiratory symptoms (wheeze, mucus
hypersecretion and unspecific respiratory pro-
blems).
However, on the basis of the results from other
groups6,17 we also, as an ad hoc study, isolated the
group of smokers that reported mucus hypersecre-
tion when approached with the questionnaire ðn ¼
12Þ: In subjects with hypersecretion, the correla-
tions between the total number of mast cells
and lung function tests (TLC, RV), were significant
(Fig. 4), whereas no correlation between mast cells
and lung function were discernible in the group
without hypersecretion (results not shown).
Discussion
This study aimed at further investigating our
findings of mast cell occurrence and structural
changes linked to these cells, in central bronchial
biopsies in asymptomatic smokers.20 On the basis
of this, the numbers of mast cells in three different
mucosal compartments (epithelium, lamina
propria and smooth muscle) were studied in
relation to structural changes, smoking habits, lung
function and emphysema. Our main findings
were a close relationship between mast cells in
the smooth muscle compartment to structural
changes and to lung functions such as FRC, TLC
and RV. However, no correlation could be detected
between mast cells and FEV1 or to emphysema on
HRCT. Our data suggest a mast cell myositis in
smokers.
In this study we evaluated mast cells in various
mucosal compartments in the biopsies, i.e. the
epithelium, the lamina propria and the smooth
muscle. Although we found correlations between
numbers of mast cells in most compartments and
structural changes, the strongest correlations were
seen for the occurrence of mast cells in the smooth
muscle compartment and in particular to the
thickness of the laminin layer. Our data indicate
that mast cell myositis could be important also for
structural changes in the airways with ‘‘remodel-
ling’’ indicated by the changes we see in the basal
membrane. It must however be realised that our
findings do not establish a cause-relationship
between mast cells and the development of further
tissue changes. The possibility of mast cells
occurring as an epiphenomenon to, i.e. an eosino-
phil increase, is still possible. Interestingly, in
asthma a recent report showed a relationship
between smooth muscle accumulation of mast cells
and bronchial hyperresponsiveness,19 indicating a
central mast cell myositis as important in that
disease.
Most studies did not find differences between
smokers and never-smokers or in smokers with and
without COPD in the occurrence of mast cells, in
peripheral bronchial7–9,15,29 or in operative biop-
sies.30 Some studies, however, showed significantly
more mast cells in smokers with chronic bronchitis
compared to never-smokers in bronchial biopsies17
and in operative biopsies in smokers with COPD
compared to those without C0PD.16 Our data
support these last findings, especially as we also
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Table 3 Correlations between number of mast cells in different mucosal compartments and lung function test in
smokers (n¼ 29).
Epithelium Lamina propria Smooth muscle
Rs P-value Rs P-value Rs P-value
TLC 0.11 0.56 0.35 0.08 0.44 0.017
RV 0.24 0.21 0.31 0.10 0.41 0.03
FRC 0.12 0.53 0.43 0.02 0.60 0.0006
VC 0.015 0.93 0.29 0.12 0.32 0.09
FEV1 0.23 0.24 0.09 0.64 0.11 0.58
(All values are expressed as % of predicted, Rs¼ Spearman rank correlation coefficient, P according to the Spearman rank
correlation test).
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found correlations between mast cells and lung
function tests in smokers reporting hypersecretion,
when approached with a questionnaire, but not in
smokers without this. Further, another link be-
tween mast cells and hypersecretion is that
tryptase has been found to have a secretagogue
effect in the airways.31 It is therefore possible that
the occurrence of mast cells is a factor contributing
to phlegm production in smokers.
Our findings of close correlations between mast
cell numbers in the smooth muscle compartment of
smokers and lung functions such as FRC, TLC and RV
are unexpected and interesting. These findings
could relate to the structural remodelling changes
mentioned above. The increase in FRC could
possibly be a finding indicating further develop-
ment to the more severe increase in FRC seen in
fully developed COPD.32 The lack of relation in our
data with emphysematous changes on HRCT may
indicate that the increase of FRC occurs earlier in
the development of disease than emphysematous
changes as visualised by HRCT. It is generally
considered that emphysema development in COPD
is a release of tissue destructive products from
neutrophils and macrophages. Probably this occurs
later in the progression of the disease than the
mast cell driven changes we have seen structurally
in the tissues and physiologically as change of FRC
and RV. A hypothesis for further testing could be
that mucosal mast cells are involved in a pre-
emphysematous stage of disease development.
Another possibility is that there are different
phenotypes of reactions to smoking. One early
reaction could be neutrophil-macrophage domi-
nated pathogenetic events with physiologic dete-
rioration mainly seen as a decrease of diffusion5
and consequent development of emphysematous
changes.5 Another route of development could be
mast cell accumulation and activation and subseg-
ment changes of FRC and RV. It would have been
interesting to study any change of bronchial hyper-
responsiveness related to a mast cell occurrence,19
in the current study. However, that was not feasible
in the study.
We have earlier demonstrated that several
inflammatory cells, neutrophils, eosinophils, mast
cells and macrophages, are increased in asympto-
matic smokers compared to never-smokers.20 In the
present paper, we have shown that smoking is
associated with an increase of the numbers of mast
cell, which is correlated to various lung function
tests measuring hyperinflation (FRC, TLC, RV). Our
study also have demonstrated that these relations
were most obvious for mast cells located in the
smooth muscle, suggesting the mast cell myositis
causally related to both ‘‘remodelling’’ of the
bronchi and changes in lung functions. If there is
any relation between this mast cell myositis and
the development of COPD remains to be further
studied.
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Figure 4 Correlations between (a) functional residual capacity (FRC) (% predicted); (b) total lung capacity (TLC) (%
predicted); (c) residual volume (RV) (% predicted), and the total number of mast cells per mm2 in smokers with mucus
hypersecretion ðn ¼ 12Þ (Rs¼ Spearman rank correlation coefficient, P according to the Spearman rank correlation
test).
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